恒瑞医药与 Glenmark Specialty 公司签署瑞康曲妥珠单抗项目授权许可协议

Core Viewpoint - The agreement between 恒瑞医药 and Glenmark Specialty allows for the exclusive licensing of the innovative drug 瑞康曲妥珠单抗 (SHR-A1811) for commercialization outside specified regions, enhancing the drug's global market reach and potential revenue for the company [1][2] Group 1: Agreement Details - 恒瑞医药 grants Glenmark Specialty the exclusive rights to develop and commercialize 瑞康曲妥珠单抗 in all regions except for China, the US, Canada, Europe, Japan, and several other specified countries [1] - Glenmark Specialty will pay a $18 million upfront fee and could pay up to $1.093 billion in milestone payments related to registration and sales [1] - Sales commissions will be paid to 恒瑞医药 based on the sales performance of 瑞康曲妥珠单抗 within the licensed territories [1] Group 2: Strategic Implications - The agreement is expected to broaden the overseas market for 瑞康曲妥珠单抗, providing high-quality treatment options for global patients [2] - The company aims to enhance its innovative brand and international performance through a strategy that combines independent research and open collaboration [2] - By leveraging partnerships with leading international firms, the company seeks to accelerate the transformation of its R&D achievements and maximize product value in the global pharmaceutical innovation network [2]